CPRXHealthcare · BiotechnologyCPRX Stock Forecast: Catalyst Pharmaceuticals, Inc. Price Predictions for 2026-2027
The 4 Wall Street analysts covering Catalyst Pharmaceuticals, Inc. hold a median 12-month price target of $32 — +0.0% from the last close.
CPRX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Catalyst Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
We don’t hold a current model rank for this company.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
CPRX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CPRX, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +0.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 May 2026 | HC Wainwright & Co. | Downgrade | Neutral | $35 → $32 |
| 8 May 2026 | Citigroup | Downgrade | Neutral | — |
| 7 May 2026 | Stephens & Co. | Downgrade | Equal-Weight | — |
| 3 Mar 2026 | Citigroup | Maintains | Buy | — |
| 7 Nov 2025 | Citigroup | Maintains | Buy | — |
| 3 Mar 2025 | Baird | Maintains | Outperform | — |
| 28 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Feb 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 4 Feb 2025 | Baird | Initiates | Outperform | — |
| 10 Jan 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Jan 2025 | B of A Securities | Reiterates | Buy | — |
| 18 Nov 2024 | Stephens & Co. | Initiates | Overweight | — |
| 11 Nov 2024 | Truist Securities | Maintains | Buy | — |
| 8 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Aug 2024 | Citigroup | Maintains | Buy | — |
| 9 Aug 2024 | Truist Securities | Maintains | Buy | — |
| 6 June 2024 | Oppenheimer | Reiterates | Outperform | — |
| 3 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CPRX appears on the weeks it earns a place.
CPRX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Catalyst Pharmaceuticals, Inc. (CPRX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 18.2×
- Price / sales
- 6.5×
- Price / book
- 3.8×
- EV / EBITDA
- 10.1×
Cheaper than 41% of US stocks
Cheaper than 21% of US stocks
Cheaper than 28% of US stocks
Cheaper than 38% of US stocks
- Revenue growth (YoY)
- 5.6%
- Earnings growth (YoY)
- 12.3%
- Gross margin
- 90.3%
- Operating margin
- 49.0%
- Net margin
- 37.1%
Higher than 40% of US stocks
Higher than 51% of US stocks
Higher than 96% of US stocks
Higher than 96% of US stocks
Higher than 93% of US stocks
- Return on equity
- 24.5%
- Return on assets
- 16.3%
- Dividend yield
- —
Higher than 85% of US stocks
Higher than 98% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
CPRX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| CPRXCatalyst Pharmaceuticals, Inc. | $3.9B | — |
| LLYEli Lilly & Co.* | $1.2T | 91 |
| JNJJohnson & Johnson* | $650.8B | 92 |
| ABBVAbbVie, Inc.* | $468.1B | 96 |
| MRKMerck & Co., Inc.* | $378.6B | 83 |
| UNHUnitedHealth Group, Inc.* | $353.4B | 75 |
| AMGNAmgen, Inc.* | $236.8B | 92 |
* Nearest Healthcare names by size — few biotechnology companies of this scale trade in the US universe.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Catalyst Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about CPRX stock
What is the CPRX stock price forecast for 2026-2027?
The 4 Wall Street analysts covering Catalyst Pharmaceuticals, Inc. have a median 12-month price target of $32, with estimates ranging from $32 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CPRX stock a buy right now?
Of the 4 analysts covering Catalyst Pharmaceuticals, Inc., 0 rate it a Buy, 4 a Hold and 0 a Sell. None of this is personal advice — it does not consider your circumstances.
Will CPRX stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts implies +0.0% from the last close. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CPRX stock forecast for 2030?
No analyst covering Catalyst Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CPRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $32 over the next 12 months.
What does Catalyst Pharmaceuticals, Inc. do?
Catalyst Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, particularly in neuromuscular, neurological, and metabolic areas.
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, particularly in neuromuscular, neurological, and metabolic areas. Its primary products include FIRDAPSE (amifampridine phosphate), approved for treating Lambert-Eaton Myasthenic Syndrome (LEMS); AGAMREE (vamorolone), a corticosteroid for Duchenne muscular dystrophy; and FYCOMPA (perampanel), used for focal onset seizures and tonic-clonic seizures. The company emphasizes patient accessibility through comprehensive support services, patient advocacy, and community-building initiatives to ensure seamless treatment access. Catalyst Pharmaceuticals Inc. maintains a strong U.S. commercial presence while pursuing strategic partnerships for global expansion. Guided by core values of passion, trust, and integrity, it prioritizes ethical standards and innovative therapies addressing unmet needs in small patient populations. Founded and headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals Inc. plays a vital role in the rare disease sector by delivering targeted treatments that improve patient outcomes.
CEO Mr. Richard John Daly M.B.A. · 182 employees · United States · https://catalystpharma.com